Publications by authors named "Zahidah Abu Seman"
Objective: Mutational analysis of BCR::ABL1 kinase domain (KD) is a crucial component of clinical decision algorithms for chronic myeloid leukemia (CML) patients with failure or warning responses to tyrosine kinase inhibitor (TKI) therapy. This study aimed to detect BCR::ABL1 KD mutations in CML patients with treatment resistance and assess the concordance between NGS (next generation sequencing) and Sanger sequencing (SS) in detecting these mutations.
Results: In total, 12 different BCR::ABL1 KD mutations were identified by SS in 22.
Background: Relapsed acute myeloid leukemia (AML) is associated with the acquisition of additional somatic mutations which are thought to drive phenotypic adaptability, clonal selection and evolution of leukemic clones during treatment. We performed high throughput exome sequencing of matched presentation and relapsed samples from 6 cytogenetically normal AML (CN-AML) patients treated with standard remission induction chemotherapy in order to contribute with the investigation of the mutational landscape of CN-AML and clonal evolution during AML treatment.
Result: A total of 24 and 32 somatic variants were identified in presentation and relapse samples respectively with an average of 4.
Objective: The most frequent acquired molecular abnormalities and important prognostic indicators in patients with Acute Myeloid Leukaemia (AML) are fms-like tyrosine kinase-3 gene (FLT3) and nucleophosmin-1 (NPM1) mutations. Our study aims to develop a cost effective and comprehensive in-house conventional PCR method for detection of FLT3-ITD, FLT3-D835 and NPM1 mutations and to evaluate the frequency of these mutations in patients with cytogenetically normal (CN) AML in our population. Methods: A total of 199 samples from AML patients (95 women, 104 men) were included in the study.
View Article and Find Full Text PDFArticle Synopsis
- Chronic Myeloid Leukemia (CML) is linked to a specific gene mutation (BCR-ABL) that affects treatment response, notably with the T315I mutation leading to resistance against the drug Imatinib Mesylate (IM).
- A study of 285 Malaysian CML patients found that 5.26% had the T315I mutation, with varying stages of the disease represented among the positive cases.
- The results highlight the importance of mutation testing to tailor effective treatment options, particularly with different tyrosine kinase inhibitors, to manage CML and prevent progression.